Samuel Rogers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4954983/publications.pdf

Version: 2024-02-01

840776 1125743 1,122 14 11 13 citations h-index g-index papers 16 16 16 3370 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer. Clinical Epigenetics, 2021, 13, 37.	4.1	14
2	Chromatin mobility and relocation in DNA repair. Trends in Cell Biology, 2021, 31, 843-855.	7.9	35
3	Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer. Cancers, 2020, 12, 2268.	3.7	15
4	The mTOR pathway: Implications for DNA replication. Progress in Biophysics and Molecular Biology, 2019, 147, 17-25.	2.9	31
5	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 2018, 37, 4518-4533.	5.9	45
6	SnapShot: Phosphoregulation of Mitosis. Cell, 2017, 169, 1358-1358.e1.	28.9	12
7	PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. Journal of Cell Science, 2016, 129, 1340-54.	2.0	44
8	Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. BioEssays, 2016, 38, S24-32.	2.5	26
9	Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. Inside the Cell, 2016, 1, 27-35.	0.4	0
10	Dataset from the global phosphoproteomic mapping of early mitotic exit in human cells. Data in Brief, 2015, 5, 45-52.	1.0	8
11	Global Phosphoproteomic Mapping of Early Mitotic Exit in Human Cells Identifies Novel Substrate Dephosphorylation Motifs. Molecular and Cellular Proteomics, 2015, 14, 2194-2212.	3.8	63
12	Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Division, 2015, 10, 1.	2.4	17
13	Partial inhibition of Cdk1 in G ₂ phase overrides the SAC and decouples mitotic events. Cell Cycle, 2014, 13, 1400-1412.	2.6	773
14	Stressing Mitosis to Death. Frontiers in Oncology, 2014, 4, 140.	2.8	39